# Lecture 3: Posterior Pituitary Disorders

## Unit 2.3: Endocrine System

---

## Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the physiology of ADH secretion and water balance
2. Explain the causes and diagnosis of diabetes insipidus
3. Describe the treatment of central and nephrogenic DI
4. Explain the pathophysiology and causes of SIADH
5. Describe the approach to hyponatremia in the context of ADH disorders
6. Explain oxytocin disorders and clinical applications

---

## Lecture Outline

### I. ADH Physiology Review

Antidiuretic hormone (ADH), also called arginine vasopressin (AVP), is the primary regulator of water balance, controlling free water reabsorption in the kidney collecting duct. Understanding normal ADH physiology is essential for comprehending the disorders of water balance that arise from either ADH deficiency or excess.

**Synthesis and release** of ADH follows a neurosecretory pathway. ADH is synthesized by magnocellular neurons in the **supraoptic nucleus (SON)** and **paraventricular nucleus (PVN)** of the hypothalamus. The hormone is packaged into vesicles along with neurophysin II and transported down axons through the pituitary stalk to the posterior pituitary, where it is stored in nerve terminals adjacent to capillaries. Release occurs in response to action potentials that propagate down these axons, causing calcium-mediated exocytosis. The half-life of circulating ADH is approximately 15-20 minutes.

**Stimuli for ADH release** are primarily osmotic, with volume and pressure stimuli serving as secondary regulators. **Increased plasma osmolality** is the primary stimulus: specialized osmoreceptors in the hypothalamus detect increases as small as 1-2% above the set point (approximately 280-290 mOsm/kg) and trigger ADH release. **Decreased blood volume** (hypovolemia exceeding 10%) activates baroreceptors in the carotid sinus, aortic arch, and left atrium, stimulating ADH release—this volume-mediated release is less sensitive but can override osmotic regulation in severe hypovolemia. **Decreased blood pressure** similarly activates arterial baroreceptors. Other stimuli include nausea (one of the most potent non-osmotic stimuli), pain, stress, and various medications (carbamazepine, SSRIs, opioids, NSAIDs).

**ADH receptors** mediate distinct effects in different tissues. **V1a receptors** on vascular smooth muscle activate the phospholipase C-IP3-calcium pathway, causing vasoconstriction—this pressor effect gives vasopressin its name, though it requires supraphysiological concentrations. **V1b receptors** (V3) in the anterior pituitary stimulate ACTH release. **V2 receptors** in the renal collecting duct are the primary mediators of the antidiuretic effect: ADH binding activates adenylyl cyclase via Gs protein, increasing cAMP, which triggers insertion of **aquaporin-2 (AQP2)** water channels into the apical membrane of principal cells. This allows water to flow from the tubular lumen into the hypertonic medullary interstitium, concentrating the urine and retaining body water.

<image>Panel A: ADH synthesis pathway showing magnocellular neurons in supraoptic and paraventricular nuclei of hypothalamus, axonal transport through pituitary stalk, and storage in posterior pituitary terminals adjacent to fenestrated capillaries. Panel B: Stimuli for ADH release including osmoreceptors (primary, detecting osmolality >280-290 mOsm/kg), baroreceptors (secondary, detecting >10% volume loss), and other stimuli (nausea, pain, medications). Panel C: V2 receptor mechanism in collecting duct principal cells showing ADH binding, Gs-cAMP-PKA signaling cascade, and aquaporin-2 vesicle trafficking to apical membrane for water reabsorption. Panel D: Medullary osmotic gradient from 300 to 1200 mOsm/kg enabling urine concentration, with V1a receptor vasoconstriction mechanism comparison.</image>

---

### II. Diabetes Insipidus - Overview

Diabetes insipidus (DI) is a disorder characterized by polyuria (excessive urine output) and polydipsia (excessive thirst) resulting from impaired ability to concentrate urine. The name, meaning "insipid" or "tasteless urine," distinguishes this condition from diabetes mellitus ("honey-sweet urine").

**Definition and quantification** establish that true polyuria exceeds 3 liters per day in adults, though patients with DI often produce 5-20 liters of dilute urine daily. Urine osmolality is inappropriately low (typically <300 mOsm/kg, often <100 mOsm/kg) despite elevated or high-normal serum osmolality. The mechanism involves either deficient ADH production or renal resistance to ADH action.

**Types of diabetes insipidus** reflect different pathophysiological mechanisms. **Central DI** (also called neurogenic or cranial DI) results from inadequate ADH synthesis or release by the hypothalamus and posterior pituitary. **Nephrogenic DI** results from kidney resistance to the action of ADH despite adequate circulating hormone levels. **Primary polydipsia** (psychogenic polydipsia or dipsogenic DI) is not true DI but must be distinguished; patients drink excessively, suppressing ADH release and diluting urine appropriately. **Gestational DI** is a rare pregnancy-specific condition caused by placental vasopressinase, an enzyme that degrades ADH.

**Central DI causes** span multiple etiologies. **Idiopathic** cases account for 30-50%, though some may represent undetected autoimmune hypophysitis. **Neurosurgery** (particularly transphenoidal surgery or procedures involving the hypothalamus) is the most common identifiable acquired cause; DI may be transient or permanent depending on the extent of damage. **Tumors** including craniopharyngioma, germinoma, pituitary adenoma, and metastases (particularly breast and lung) can damage the hypothalamic-pituitary axis. **Trauma** (traumatic brain injury) damages the stalk or hypothalamus. **Infiltrative diseases** including sarcoidosis, Langerhans cell histiocytosis, and tuberculosis may involve the hypothalamus. **Autoimmune lymphocytic infundibuloneurohypophysitis** is increasingly recognized. **Genetic causes** include autosomal dominant mutations in the AVP gene causing progressive central DI from neurodegeneration.

**Nephrogenic DI causes** involve mechanisms that impair the kidney's response to ADH. **Genetic forms** include X-linked nephrogenic DI (V2 receptor mutations, severe phenotype) and autosomal nephrogenic DI (aquaporin-2 mutations). **Lithium** is the most common acquired cause—it enters principal cells and interferes with signaling and aquaporin-2 expression; 40% of patients on chronic lithium develop some degree of concentrating defect. Other medications include amphotericin B, foscarnet, and demeclocycline (which was historically used to treat SIADH by inducing nephrogenic DI). **Hypercalcemia** and **hypokalemia** impair concentrating ability. **Chronic kidney disease** and **post-obstructive uropathy** cause concentrating defects. **Sickle cell disease** damages the renal medulla.

<image>Panel A: Central versus nephrogenic DI mechanism showing hypothalamic-pituitary-renal axis with central DI defect at ADH release (broken arrow from brain) and nephrogenic DI defect at kidney response (blocked arrow at collecting duct). Panel B: Central DI causes including idiopathic (30-50%), neurosurgery, tumors (craniopharyngioma, metastases), trauma, infiltrative diseases (sarcoidosis, histiocytosis), autoimmune hypophysitis, and genetic AVP mutations. Panel C: Nephrogenic DI causes including genetic forms (X-linked V2 receptor, autosomal AQP2), lithium (40% incidence), other drugs (amphotericin, foscarnet), hypercalcemia, hypokalemia, CKD, and sickle cell disease. Panel D: Primary polydipsia contrast showing excessive water intake appropriately suppressing ADH with dilute urine, distinguishing it from true DI.</image>

---

### III. Diabetes Insipidus - Clinical Features

The clinical presentation of DI reflects the body's attempt to compensate for massive water losses through increased thirst and water intake, with decompensation occurring when intake cannot match losses.

**Symptoms** center on the polyuria-polydipsia axis. **Polyuria** is the hallmark—patients report frequent, large-volume urinations both day and night, often exceeding 5-10 liters daily in complete DI. Urine is described as clear and dilute, like water. **Polydipsia** represents the compensatory response: patients experience intense, insatiable thirst and crave ice-cold water specifically (a somewhat specific feature). **Nocturia** disrupts sleep as patients awaken multiple times to void and drink. Patients may report fatigue and decreased concentration from sleep disruption.

**Signs** depend on whether the patient can adequately compensate by drinking. When access to water is unlimited and thirst mechanism is intact, patients maintain relatively normal volume status despite massive throughput—they essentially "drink and urinate" continuously. Physical examination may be unremarkable or show signs of frequent bathroom visits. When water access is limited or thirst is impaired, **dehydration** develops: tachycardia, orthostatic hypotension, decreased skin turgor, dry mucous membranes. Mental status changes (confusion, lethargy, irritability) occur with developing **hypernatremia**.

**When DI becomes dangerous** relates to situations preventing adequate water intake. **Unconscious patients** cannot drink to compensate for losses, leading to rapid hypernatremia. **Patients with impaired thirst** (hypothalamic lesions affecting the thirst center, elderly patients with diminished thirst sensation) may not drink adequately despite having water available. **Infants** depend on caregivers to provide water. **Hospitalized patients** may have intake restricted or controlled. In these situations, serum sodium can rise precipitously (>160-170 mEq/L), causing neurologic symptoms from brain cell shrinkage: confusion, lethargy, seizures, and coma.

**Laboratory findings** in untreated or decompensated DI show **elevated serum sodium** (hypernatremia) and **elevated serum osmolality** (>295 mOsm/kg), while **urine osmolality is inappropriately low** (<300 mOsm/kg, often <100 mOsm/kg)—the hallmark is dilute urine in the face of concentrated serum. **Urine specific gravity** is low (<1.005). In compensated DI with adequate water intake, serum sodium and osmolality may be in the high-normal range rather than overtly elevated.

<image>Panel A: Polyuria-polydipsia cycle showing 24-hour urine output exceeding 3L threshold (DI patients 5-20L range), dilute colorless urine, and ice water preference as clinical clue. Panel B: Compensated versus decompensated DI comparing adequate water access with intact thirst (normal vitals, high throughput, maintained sodium) versus limited access or impaired thirst (tachycardia, orthostatic hypotension, dry mucosae, confusion). Panel C: Dangerous scenarios including unconscious patients, elderly with impaired thirst, and infants dependent on caregivers, all progressing to hypernatremia (>160-170 mEq/L) with neurologic consequences. Panel D: Laboratory comparison showing compensated DI (sodium high-normal, serum osmolality high-normal, urine osmolality <300) versus decompensated DI (sodium elevated, serum osmolality >295, urine osmolality <100).</image>

---

### IV. Diabetes Insipidus - Diagnosis

The diagnostic approach to polyuria aims to confirm true DI, distinguish central from nephrogenic forms, and identify the underlying cause.

**Initial evaluation** begins by confirming polyuria (24-hour urine collection showing >3 L/day) and excluding other causes of polyuric states. **Serum chemistry** assesses sodium (often high-normal or elevated), glucose (excludes diabetes mellitus osmotic diuresis), calcium (hypercalcemia causes polyuria), and potassium (hypokalemia impairs concentrating ability). Simultaneous measurement of **serum osmolality** and **urine osmolality** reveals the characteristic pattern: serum osmolality elevated or high-normal (>290 mOsm/kg) with urine osmolality inappropriately low (<300 mOsm/kg). In primary polydipsia, both serum and urine osmolality are low because the excess water intake dilutes everything.

The **water deprivation test** (dehydration test) remains a traditional diagnostic approach. The patient is made NPO while weight, urine output, urine osmolality, and serum osmolality are monitored. The test continues until one of three endpoints: **significant weight loss** (3-5%), **serum osmolality exceeds 295 mOsm/kg**, or **urine osmolality plateaus** (two consecutive measurements within 30 mOsm/kg). After maximum concentration is achieved, urine osmolality is assessed: values greater than 600 mOsm/kg indicate **normal concentrating ability** (consistent with primary polydipsia or partial defects); values less than 300 mOsm/kg indicate DI requiring further differentiation.

The **desmopressin (DDAVP) challenge** follows an inadequate concentrating response. Desmopressin, a synthetic ADH analog selective for V2 receptors, is administered (typically 2-4 μg subcutaneously or 10-20 μg intranasally). Urine osmolality is measured before and after. In **central DI**, urine osmolality increases by more than 50% or reaches >600 mOsm/kg as the exogenous ADH replaces the missing endogenous hormone. In **nephrogenic DI**, urine osmolality increases by less than 50% and remains dilute (<300 mOsm/kg) because the kidney cannot respond to ADH regardless of source.

**Additional tests** refine the diagnosis. **Pituitary MRI** in central DI may show absence of the normal posterior pituitary bright spot (which represents stored neurophysin-hormone complexes), stalk thickening (infiltrative disease), or causative lesions (tumors, metastases). **Plasma copeptin** is an emerging biomarker: copeptin is the C-terminal portion of the ADH precursor, secreted equimolarly with ADH but more stable. Low copeptin after dehydration or hypertonic saline confirms central DI; elevated copeptin despite dilute urine confirms nephrogenic DI. **Genetic testing** is indicated for familial cases.

<image>Panel A: Initial DI assessment showing 24-hour urine collection (>3L confirms polyuria), chemistry panel (sodium, glucose, calcium, potassium), and simultaneous serum/urine osmolality interpretation grid (high serum + low urine = DI; low serum + low urine = primary polydipsia). Panel B: Water deprivation test protocol with NPO status, monitoring of weight, urine output, and osmolalities until endpoints (3-5% weight loss, serum osmolality >295, or urine osmolality plateau), with interpretation (>600 = normal, <300 = DI). Panel C: DDAVP challenge response comparison showing central DI (urine osmolality increases >50%, reaches >600, responds to DDAVP) versus nephrogenic DI (increases <50%, remains <300, no response). Panel D: Additional diagnostic tests including pituitary MRI for absent posterior pituitary bright spot and plasma copeptin measurement (low = central DI, elevated = nephrogenic DI).</image>

---

### V. Diabetes Insipidus - Treatment

Treatment of DI aims to replace the missing hormonal effect in central DI, reduce urine output in nephrogenic DI, and prevent dangerous hypernatremia while avoiding the opposite risk of water intoxication.

**Central DI treatment** centers on desmopressin (DDAVP), a synthetic vasopressin analog. Desmopressin has two amino acid modifications that confer selective V2 receptor agonism (antidiuretic effect) with minimal V1a activity (avoiding pressor effects) and increased resistance to degradation by vasopressinases. **Routes of administration** include intranasal spray or solution (10-40 μg daily in divided doses), oral tablets (0.1-0.4 mg two to three times daily), sublingual tablets, and subcutaneous injection. Dosing is individualized, titrating to achieve control of polyuria and polydipsia while avoiding **hyponatremia from overcorrection**. A critical principle is allowing periodic "breakthrough" polyuria—intentionally letting the medication wear off to allow excess water to be excreted, preventing water accumulation and dilutional hyponatremia. Patients should be educated to recognize symptoms of hyponatremia and have sodium levels monitored.

**Nephrogenic DI treatment** is more challenging because the kidney cannot respond to ADH. **Treat underlying causes** when possible: discontinue lithium if feasible (though the concentrating defect may persist), correct hypercalcemia and hypokalemia. **Dietary modification** includes a **low-sodium diet** (reducing solute load decreases obligatory water excretion) and moderate protein restriction (reducing urea load). **Thiazide diuretics** paradoxically reduce urine volume in nephrogenic DI through mechanisms involving enhanced proximal tubular reabsorption secondary to mild volume contraction; they are often combined with a low-sodium diet. **Amiloride** is specifically useful in lithium-induced nephrogenic DI because it blocks the epithelial sodium channel (ENaC) through which lithium enters principal cells. **NSAIDs** (indomethacin) may reduce urine output by inhibiting prostaglandins that antagonize ADH action, though they carry risks of renal and gastrointestinal toxicity.

**Acute hypernatremia management** in decompensated DI requires careful free water replacement. Calculate the **free water deficit**: Free water deficit = Total body water × [(Serum Na / 140) - 1], where TBW ≈ 0.6 × body weight in males, 0.5 in females. Replace deficit using **hypotonic fluids** (D5W or 0.45% saline). The rate of correction is critical: lower sodium by **0.5-1 mEq/L per hour**, not exceeding **10-12 mEq/L per 24 hours**. Overly rapid correction in chronic hypernatremia risks **cerebral edema** as brain cells have adapted by accumulating osmolytes and will swell if sodium falls too quickly.

**Post-surgical DI** following pituitary or hypothalamic surgery often follows a characteristic **triphasic response**. **Phase 1 (DI)** occurs in days 1-5 from acute hypothalamic dysfunction causing transient ADH deficiency. **Phase 2 (SIADH)** occurs around days 5-10 as dying neurons release stored ADH, causing transient water retention. **Phase 3 (permanent DI)** occurs after day 10 if sufficient neuronal damage has occurred. Close sodium monitoring through this period allows appropriate adjustment of therapy.

<image>Panel A: Central DI treatment with desmopressin showing V2 selectivity and protease resistance, administration routes (nasal spray 10-40 mcg, oral tablet 0.1-0.4 mg, subcutaneous injection), titration to balance polyuria control with hyponatremia avoidance, and breakthrough polyuria concept. Panel B: Nephrogenic DI treatment including removal of offending agents (lithium), low-sodium diet, thiazide diuretics (paradoxical effect via proximal tubule reabsorption), amiloride for lithium-induced DI (blocks ENaC), and NSAIDs inhibiting prostaglandins. Panel C: Acute hypernatremia management with free water deficit formula, hypotonic fluid options (D5W, 0.45% saline), correction rate limits (0.5-1 mEq/L/hr, maximum 10-12 mEq/L per 24 hours), and cerebral edema warning. Panel D: Post-surgical triphasic response timeline showing Phase 1 DI (days 1-5), Phase 2 SIADH (days 5-10), and Phase 3 permanent DI (after day 10 if neuronal damage occurred).</image>

---

### VI. SIADH - Pathophysiology

The syndrome of inappropriate antidiuretic hormone secretion (SIADH) represents the opposite pathophysiology from DI: excessive ADH action causes water retention and dilutional hyponatremia. SIADH is the most common cause of euvolemic hyponatremia.

**Definition and mechanism** establish SIADH as a condition where ADH is secreted (or its effect is enhanced) despite conditions that should suppress it—specifically, low plasma osmolality and adequate or expanded volume. "Inappropriate" means the normal regulatory mechanisms are overridden. The excess ADH causes increased water reabsorption in the collecting duct, leading to water retention. However, volume expansion activates compensatory mechanisms: atrial natriuretic peptide (ANP) release promotes sodium excretion, and suppressed aldosterone reduces sodium reabsorption. The net result is **water retention with concurrent sodium wasting**, producing **euvolemic hyponatremia**—the patient appears clinically euvolemic rather than edematous because the excess water distributes throughout total body water (two-thirds intracellular).

**Diagnostic criteria** for SIADH include: **serum osmolality <275 mOsm/kg** (hypotonic, dilute), **urine osmolality >100 mOsm/kg** (inappropriately concentrated—should be maximally dilute when serum is hypotonic), **urine sodium >40 mEq/L** (indicating euvolemia and ongoing sodium excretion), **clinical euvolemia** (no edema, no signs of dehydration), and **no other cause of hyponatremia** (normal thyroid function, normal adrenal function, no diuretic use, normal kidney function). The presence of concentrated urine in the setting of serum hypotonicity is the key finding—the kidneys should be producing maximally dilute urine to excrete excess water, but cannot because of ADH action.

**Mechanism of symptoms** relates to cerebral effects of hyponatremia. Brain cells swell as water enters due to the osmotic gradient between hypotonic extracellular fluid and intracellular contents. The rigid skull limits expansion, causing increased intracranial pressure. The brain adapts over time by extruding osmolytes (sodium, potassium, organic osmolytes), allowing it to shrink back toward normal size—this adaptation explains why chronic hyponatremia is often well tolerated while acute hyponatremia causes severe symptoms. It also explains the danger of rapid correction: if sodium is raised quickly, the brain (having lost osmolytes) cannot restore them rapidly, so it shrinks excessively, causing osmotic demyelination syndrome.

<image>Panel A: SIADH mechanism showing inappropriate ADH release despite low osmolality, V2 receptor activation causing water reabsorption, volume expansion triggering ANP release and aldosterone suppression, resulting in water retention plus sodium excretion causing euvolemic hyponatremia. Panel B: Normal versus SIADH comparison showing normal response (low osmolality suppresses ADH, dilute urine) versus SIADH (low osmolality but ADH present, inappropriately concentrated urine). Panel C: Diagnostic criteria checklist including serum osmolality <275, urine osmolality >100 (inappropriately concentrated), urine sodium >40 (euvolemia), clinical euvolemia, and exclusion of other causes (normal thyroid, adrenal, renal function). Panel D: Brain adaptation showing acute hyponatremia (cell swelling, increased ICP, severe symptoms) versus chronic hyponatremia (osmolyte extrusion, adaptation, fewer symptoms but vulnerable to rapid correction causing osmotic demyelination).</image>

---

### VII. SIADH - Causes and Clinical Features

The causes of SIADH are diverse, spanning central nervous system disorders, pulmonary diseases, malignancies, and numerous medications. Clinical manifestations reflect the severity and acuity of hyponatremia.

**Causes** of SIADH are classically categorized by organ system. **Central nervous system disorders** directly affect the hypothalamic-pituitary axis: stroke (especially subarachnoid hemorrhage), meningitis, encephalitis, traumatic brain injury, and brain tumors. **Pulmonary diseases** are prominent causes: pneumonia (particularly Legionella and tuberculosis), lung abscess, positive pressure ventilation (reduces venous return, sensed as hypovolemia), and asthma exacerbations. **Malignancy** may cause SIADH through ectopic ADH production—**small cell lung cancer** is the prototypical and most common malignant cause; head and neck cancers and other neuroendocrine tumors also secrete ADH. **Medications** are an increasingly recognized cause: **SSRIs** (among the most common drug causes), **carbamazepine**, oxcarbazepine, cyclophosphamide (especially with high-volume hydration), **opioids**, **NSAIDs**, and some antipsychotics. **Post-operative states** commonly cause transient SIADH due to pain, nausea, and stress stimulating ADH release. **HIV/AIDS** and **idiopathic** causes account for additional cases.

**Clinical features** correlate with the severity and rate of onset of hyponatremia rather than absolute sodium level alone. **Mild hyponatremia** (sodium 125-134 mEq/L) is often asymptomatic or causes subtle symptoms: fatigue, mild cognitive impairment, gait instability (increased fall risk), and mild nausea. These subtle effects may be underrecognized. **Moderate hyponatremia** (sodium 120-124 mEq/L) causes more pronounced symptoms: nausea, headache, confusion, lethargy, and muscle cramps. **Severe hyponatremia** (sodium <120 mEq/L) is a medical emergency: patients may experience seizures, obtundation, coma, and respiratory arrest from brainstem herniation. **Acute versus chronic hyponatremia** is a critical distinction: acute hyponatremia (developing <48 hours) is more symptomatic because the brain has not had time to adapt; chronic hyponatremia (>48 hours) allows osmolyte extrusion and adaptation, so patients may be minimally symptomatic even with sodium <120 mEq/L.

**Brain adaptation** has therapeutic implications. In chronic hyponatremia, brain cells extrude potassium, sodium, and organic osmolytes (glutamate, myoinositol, taurine) to reduce swelling. While this adaptation protects against cerebral edema, it creates vulnerability to rapid correction: if sodium is raised faster than osmolytes can be replenished, the brain shrinks excessively, causing **osmotic demyelination syndrome (ODS)**.

<image>Panel A: SIADH causes organized by category including CNS disorders (stroke, infection, trauma), pulmonary diseases (pneumonia, TB, positive pressure ventilation), malignancy (small cell lung cancer as most common, ectopic ADH secretion), and medications (SSRIs as most common drug cause, carbamazepine, cyclophosphamide, opioids). Panel B: Hyponatremia symptom severity spectrum from mild (125-134 mEq/L: fatigue, gait instability, subtle cognitive changes) to moderate (120-124: nausea, headache, confusion, lethargy) to severe (<120: seizures, coma, respiratory arrest requiring emergency treatment). Panel C: Acute versus chronic hyponatremia comparison showing acute (<48 hours) with brain swelling and severe symptoms versus chronic (>48 hours) with brain adaptation through osmolyte extrusion, fewer symptoms but vulnerability to rapid correction. Panel D: Osmotic demyelination syndrome warning emphasizing risk with rapid correction in chronic hyponatremia and need to limit correction rate.</image>

---

### VIII. SIADH - Treatment

Treatment of SIADH aims to raise serum sodium safely while addressing the underlying cause. The urgency and method of treatment depend on symptom severity and whether hyponatremia is acute or chronic.

**General principles** establish that treatment of the underlying cause (discontinuing offending medication, treating infection, treating malignancy) is paramount when possible. The rate of sodium correction is determined by the chronicity and severity: acute hyponatremia can be corrected more rapidly, while chronic hyponatremia must be corrected slowly to avoid osmotic demyelination.

**Fluid restriction** is first-line therapy for mild, chronic SIADH. Restricting free water intake to **<1 liter per day** (often 800 mL or less) prevents further dilution and allows gradual sodium rise. However, fluid restriction is often ineffective or impractical when urine osmolality exceeds 500 mOsm/kg (the kidney is concentrating urine so efficiently that even minimal intake may maintain positive water balance) or when patients cannot adhere to severe restriction.

**Hypertonic saline (3% NaCl)** is indicated for severe symptomatic hyponatremia (seizures, coma, severe confusion). The goal is to raise sodium by **4-6 mEq/L in the first few hours** to reduce cerebral edema and relieve symptoms. The typical approach is 1-2 mL/kg/hour of 3% saline initially, with frequent sodium monitoring (every 2-4 hours). Total correction should not exceed **8-10 mEq/L in 24 hours** (some guidelines recommend 6-8 mEq/L as even safer) to minimize ODS risk. The "six in six for sick" concept suggests raising sodium by 6 mEq/L in 6 hours for severely symptomatic patients, then slowing correction.

**Vasopressin receptor antagonists (vaptans)** directly block V2 receptors, inducing free water diuresis (aquaresis) without sodium loss. **Tolvaptan** (oral) is approved for euvolemic and hypervolemic hyponatremia from SIADH, heart failure, and cirrhosis. **Conivaptan** (IV) blocks both V1a and V2 receptors. Vaptans must be initiated in hospital with close sodium monitoring because of the risk of overly rapid correction. They are useful when fluid restriction fails but are expensive and contraindicated in hypovolemic hyponatremia (where they would worsen volume depletion).

**Other treatments** include **salt tablets plus loop diuretics**, which increases solute excretion and reduces the kidney's ability to concentrate urine. **Demeclocycline** induces a nephrogenic DI-like state by blocking ADH action but is rarely used due to nephrotoxicity and hepatotoxicity. **Urea** creates an osmotic diuresis, promoting free water excretion; it is used in some European centers.

**If overcorrection occurs** (sodium rises too rapidly), intervention is needed to re-lower sodium. **Desmopressin** (1-2 μg IV or SC every 6-8 hours) replaces ADH effect, preventing further free water loss. **D5W** (5% dextrose in water) provides free water to re-lower sodium. The goal is to "reverse" the overcorrection before osmotic demyelination develops.

<image>Panel A: SIADH treatment selection by severity showing mild/chronic (fluid restriction <1 L/day, note ineffective if urine osmolality >500), moderate (add vaptans or salt tablets plus loop diuretics), and severe/symptomatic (hypertonic 3% saline as emergency treatment). Panel B: Hypertonic saline protocol with 1-2 mL/kg/hr initially, goal sodium rise 4-6 mEq/L in first hours for symptom relief, monitoring every 2-4 hours, maximum 8-10 mEq/L in 24 hours, and safe versus dangerous correction trajectories. Panel C: Vaptan therapy showing tolvaptan V2 receptor blockade mechanism promoting aquaresis, requirement for hospital initiation with monitoring, and contraindication in hypovolemia. Panel D: Overcorrection management using DDAVP (1-2 mcg) to stop free water loss plus D5W infusion to re-lower sodium to safe trajectory, preventing osmotic demyelination syndrome.</image>

---

### IX. Approach to Hyponatremia

Hyponatremia (serum sodium <135 mEq/L) is the most common electrolyte abnormality in hospitalized patients. A systematic approach based on volume status and urine studies distinguishes the many causes and guides appropriate therapy.

**Classification by volume status** is the essential first step. Assess the patient clinically for signs of volume depletion (tachycardia, orthostatic hypotension, dry mucous membranes, decreased skin turgor) or volume overload (peripheral edema, elevated JVP, pulmonary rales). **Hypovolemic hyponatremia** results from losses of both sodium and water, with sodium loss exceeding water loss—causes include GI losses (vomiting, diarrhea), renal losses (diuretics, mineralocorticoid deficiency, salt-wasting nephropathy), and third-spacing. **Euvolemic hyponatremia** involves excess water without clinically apparent volume change—SIADH is the classic cause, along with hypothyroidism, adrenal insufficiency, and primary polydipsia. **Hypervolemic hyponatremia** occurs in edematous states where both total body sodium and water are increased, but water more so—causes include congestive heart failure, cirrhosis, and nephrotic syndrome.

**Urine studies** help differentiate causes within volume categories. **Urine sodium <20 mEq/L** suggests appropriate renal sodium conservation: extrarenal losses (GI losses in hypovolemia) or decreased effective circulating volume (heart failure, cirrhosis in hypervolemia). **Urine sodium >20 mEq/L** suggests renal sodium wasting: diuretics, mineralocorticoid deficiency, salt-wasting nephropathy in hypovolemia; SIADH in euvolemia. **Urine osmolality** distinguishes primary polydipsia (urine osm <100, maximally dilute) from SIADH (urine osm >100, inappropriately concentrated).

**Euvolemic hyponatremia differential** requires additional evaluation. Check **TSH** (hypothyroidism causes impaired free water excretion). Check **cortisol** (adrenal insufficiency causes hyponatremia through both mineralocorticoid and glucocorticoid deficiency; cortisol deficiency impairs free water excretion). If thyroid and adrenal function are normal, urine sodium is high, and urine osmolality is inappropriately concentrated, SIADH is likely. **Primary polydipsia** presents with maximally dilute urine (osm <100) because ADH is appropriately suppressed—the problem is intake, not ADH excess. **Reset osmostat** is a physiological variant (sometimes seen in pregnancy) where the setpoint for ADH release is lowered, causing a new stable, mildly low sodium.

**Osmotic demyelination syndrome (ODS)**, formerly called central pontine myelinolysis, is the dreaded complication of overly rapid sodium correction in chronic hyponatremia. The **central pons** is most commonly affected, though extrapontine areas can also demyelinate. Symptoms appear **days after correction**: dysarthria, dysphagia, quadriparesis, locked-in syndrome. MRI shows characteristic demyelination. **Prevention** is paramount: limit correction to <8-10 mEq/L in 24 hours for chronic hyponatremia.

<image>Panel A: Hyponatremia classification by volume status showing hypovolemic (tachycardia, orthostasis, dry mucosae; GI loss, diuretics, adrenal insufficiency), euvolemic (normal exam; SIADH, hypothyroidism, adrenal insufficiency, primary polydipsia), and hypervolemic (edema, elevated JVP, rales; CHF, cirrhosis, nephrotic syndrome). Panel B: Urine studies interpretation with decision tree using urine sodium (<20 = extrarenal loss or low effective circulating volume; >20 = renal loss or SIADH) and urine osmolality (<100 = primary polydipsia; >100 = SIADH). Panel C: Euvolemic hyponatremia workup including TSH, cortisol, and urine studies to exclude hypothyroidism and adrenal insufficiency before diagnosing SIADH. Panel D: Osmotic demyelination syndrome showing pontine demyelination on MRI, timeline from overcorrection through symptom-free interval to dysarthria, dysphagia, and quadriparesis, with prevention emphasis on limiting correction to <8-10 mEq/L per 24 hours.</image>

---

### X. Oxytocin Physiology and Disorders

Oxytocin, the second posterior pituitary hormone, plays essential roles in reproduction, lactation, and social bonding. Disorders of oxytocin are less common than ADH disorders but have important clinical applications.

**Oxytocin functions** center on reproduction and social behaviors. In **milk ejection (let-down)**, oxytocin causes contraction of myoepithelial cells surrounding breast alveoli, propelling milk into the ducts and toward the nipple for breastfeeding. In **uterine contraction**, oxytocin stimulates rhythmic contractions of uterine smooth muscle during labor and immediately postpartum, aiding delivery and reducing hemorrhage through uterine involution. Emerging research suggests roles in **social bonding**, trust, and maternal behavior.

**Release stimuli** demonstrate neuroendocrine integration. **Suckling** is the primary stimulus for the milk ejection reflex: sensory afferents from the nipple travel to the hypothalamus, triggering oxytocin release, which causes myoepithelial contraction within seconds. This is a rapid neuroendocrine reflex. **Cervical stretch** during labor triggers the **Ferguson reflex**, one of the few examples of positive feedback in physiology: cervical dilation stimulates oxytocin release, which increases uterine contractions, which causes further cervical dilation, which triggers more oxytocin release—this positive feedback loop continues until delivery terminates the stimulus. **Psychological factors** can also trigger oxytocin release: anticipation of breastfeeding, hearing an infant cry, or even thinking about one's baby can initiate the let-down reflex.

**Clinical uses of oxytocin** are primarily obstetric. **Pitocin** (synthetic oxytocin) is used for **labor induction** and **augmentation** of inadequate labor. It is administered intravenously with careful titration and monitoring for uterine hyperstimulation. **Postpartum hemorrhage** is treated with oxytocin as a first-line uterotonic to promote uterine contraction and reduce bleeding. **Nasal oxytocin spray** is sometimes used for inadequate milk let-down, though this is uncommon. Research is ongoing into oxytocin for autism spectrum disorder and social anxiety, though clinical applications remain limited.

**Oxytocin excess** is primarily iatrogenic. At high doses, especially with prolonged infusion, oxytocin can cause **water intoxication and hyponatremia** because oxytocin has structural similarity to ADH and can activate V2 receptors, causing water retention. This is exacerbated when oxytocin is administered with large volumes of hypotonic fluids during labor. Prevention involves using isotonic fluids, limiting the duration and dose of oxytocin infusion, and monitoring fluid balance. **Oxytocin deficiency** is rarely clinically significant; women may have difficulty with breastfeeding, but other factors are more commonly responsible.

<image>Panel A: Oxytocin functions showing breast anatomy with myoepithelial cells surrounding alveoli contracting for milk ejection (let-down), and uterine smooth muscle layers with rhythmic contractions during labor and postpartum for delivery and hemostasis. Panel B: Release reflexes including suckling reflex pathway (nipple sensory afferents to hypothalamus to oxytocin release to milk ejection within seconds) and Ferguson reflex positive feedback loop (cervical stretch to oxytocin to uterine contraction to more stretch, terminated by delivery). Panel C: Clinical applications including Pitocin IV infusion for labor induction/augmentation with monitoring for hyperstimulation, and first-line treatment for postpartum hemorrhage promoting uterine contraction. Panel D: Water intoxication risk with high-dose oxytocin plus hypotonic fluids causing V2 receptor cross-activation and hyponatremia, with prevention strategies (isotonic fluids, dose limits, fluid balance monitoring).</image>

---

## Summary

ADH, synthesized in the hypothalamus and released from the posterior pituitary, is the primary regulator of water balance, acting on V2 receptors in the collecting duct to insert aquaporin-2 and promote water reabsorption. Release is triggered by increased osmolality, decreased volume, or decreased blood pressure.

Central DI results from ADH deficiency (neurosurgery, tumors, trauma, infiltrative disease, idiopathic), while nephrogenic DI results from kidney resistance to ADH (lithium, genetic causes, hypercalcemia). Both cause polyuria and polydipsia with dilute urine despite elevated serum osmolality. Central DI responds to desmopressin; nephrogenic DI requires thiazides, amiloride, and dietary modification.

SIADH is characterized by euvolemic hyponatremia with inappropriately concentrated urine and elevated urine sodium. Causes include CNS disorders, pulmonary disease, small cell lung cancer, and medications (SSRIs, carbamazepine). Treatment involves fluid restriction, hypertonic saline for severe symptoms, and vaptans.

Hyponatremia evaluation requires assessment of volume status (hypovolemic, euvolemic, hypervolemic) and urine studies. Correction must be slow in chronic hyponatremia (<8-10 mEq/L per 24 hours) to prevent osmotic demyelination syndrome.

Oxytocin mediates milk ejection and uterine contraction. Synthetic oxytocin (Pitocin) is used for labor induction and postpartum hemorrhage. High-dose oxytocin can cause water intoxication through V2 receptor cross-activation.

---

## Key Terms

| Term | Definition |
|------|------------|
| Diabetes insipidus | Disorder characterized by polyuria and polydipsia from impaired urine concentration |
| Central DI | DI from inadequate ADH production by hypothalamus/posterior pituitary |
| Nephrogenic DI | DI from kidney resistance to ADH action |
| SIADH | Syndrome of inappropriate ADH secretion causing euvolemic hyponatremia |
| Desmopressin (DDAVP) | Synthetic ADH analog selective for V2 receptors; treatment for central DI |
| Vaptan | V2 receptor antagonist causing aquaresis; treatment for SIADH |
| Osmotic demyelination syndrome | Brain injury from overly rapid sodium correction in chronic hyponatremia |
| Copeptin | Biomarker reflecting ADH secretion; useful in DI diagnosis |

---

*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*